Alterity Therapeutics Launches to Asian Investors

MELBOURNE, Australia & SAN FRANCISCO–(BUSINESS WIRE)–Alterity Therapeutics Limited, (formerly Prana Biotechnology Limited)
(ASX: PBT, NASDAQ: ATHE) (“Alterity” or “the Company”) is meeting this
week with sophisticated investors in both Singapore and Hong Kong in the
first leg of a global investor roadshow.

Alterity is developing first-in-class therapies to treat
neurodegenerative diseases including its lead drug candidate, PBT434 for
the treatment of Parkinsonian disorders.

PBT434 has received Orphan Drug designation for the first of its disease
targets, Multiple System Atrophy.

Alterity is presenting at the Spark Plus Asia Healthcare Day in
Singapore today and Hong Kong on Friday.

Highlights of the investor presentation:

• Alterity is a well-funded clinical stage drug development company
  following up to $44M strategic investment led by Life Biosciences LLC
  allowing accelerated and focused clinical development;
• A strong and highly experienced board and management team with
  significant R&D and commercialisation experience including 3 drug
  approvals by the US Food & Drugs Administration (FDA);
• Alterity’s lead drug under development PBT434, is a novel drug
  candidate targeting key proteins implicated in neurodegeneration of
  Parkinson’s disease and atypical parkinsonism;
• PBT434 is completing its Phase 1 clinical trial program;
• The first therapeutic target has been selected – Multiple System
  Atrophy (MSA), a form of atypical parkinsonism, which is a devastating
  disease with no approved treatments;
• The US FDA has designated Orphan Drug status for PBT434 for the
  treatment of MSA; and
• There is a significant commercial market potential PBT434 with MSA
  alone having an estimated peak sales of US$750M.

Mr. Geoffrey Kempler, CEO and Chairman said: “This is an exciting new
chapter for our company with a Phase 1 clinical trial program nearing
completion and the backing of a significant cornerstone investor in Life
Biosciences.”

“We have a comprehensive program to engage with investors to support
both our NASDAQ and ASX listing and company that is well poised to
capitalise on the large unmet need of treatment options for people
suffering from forms of Parkinson’s disease.”

The Company changed its name on 8 April 2019 from Prana Biotechnology
Limited to Alterity Therapeutics Limited, (NASDAQ:ATHE) and anticipates
the new ticker code ASX:ATH will shortly be announced.

Investors interested in meeting with Mr. Kempler and Dr Stamler MD, can
contact [email protected]

About Alterity Therapeutics Limited

Alterity’s lead candidate, PBT434, is the first of a new generation of
small molecules designed to inhibit the aggregation of pathological
proteins implicated in neurodegeneration. PBT434 has been shown to
reduce abnormal accumulation of α-synuclein and tau proteins in animal
models of disease by restoring normal iron balance in the brain. In this
way, it has excellent potential to treat various forms of atypical
Parkinsonism such as Multiple System Atrophy (MSA) and Progressive
Supranuclear Palsy (PSP).

For further information please visit the Company’s web site at www.alteritytherapeutics.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the
meaning of section 27A of the Securities Act of 1933 and section 21E of
the Securities Exchange Act of 1934. The Company has tried to
identify such forward-looking statements by use of such words as
“expects,” “intends,” “hopes,” “anticipates,” “believes,” “could,”
“may,” “evidences” and “estimates,” and other similar expressions, but
these words are not the exclusive means of identifying such statements.

Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements are
described in the sections titled “Risk Factors” in the Company’s filings
with the SEC, including its most recent Annual Report on Form 20-F as
well as reports on Form 6-K, including, but not limited to the
following: statements relating to the Company’s drug development
program, including, but not limited to the initiation, progress and
outcomes of clinical trials of the Company’s drug development program,
including, but not limited to, PBT434, and any other statements that are
not historical facts. Such statements involve risks and
uncertainties, including, but not limited to, those risks and
uncertainties relating to the difficulties or delays in financing,
development, testing, regulatory approval, production and marketing of
the Company’s drug components, including, but not limited to, PBT434,
the ability of the Company to procure additional future sources of
financing, unexpected adverse side effects or inadequate therapeutic
efficacy of the Company’s drug compounds, including, but not limited to,
PBT434, that could slow or prevent products coming to market, the
uncertainty of patent protection for the Company’s intellectual property
or trade secrets, including, but not limited to, the intellectual
property relating to PBT434.

Any forward-looking statement made by us in this press release is
based only on information currently available to us and speaks only as
of the date on which it is made. We undertake no obligation to
publicly updated any forward-looking statement, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.

Contacts

Investor Relations
Rebecca Wilson
E: [email protected]
Tp:
+61 3 9866 4722